Aclaris Therapeutics, Inc. (LON: 0H8T)
London
· Delayed Price · Currency is GBP · Price in USD
2.510
+0.011 (0.44%)
Jan 22, 2025, 6:28 PM BST
Aclaris Therapeutics Employees
As of December 30, 2023, Aclaris Therapeutics had 91 total employees, including 86 full-time and 5 part-time employees. The number of employees decreased by 14 or -13.33% compared to the previous year.
Employees
91
Change (1Y)
-14
Growth (1Y)
-13.33%
Revenue / Employee
227.01K GBP
Profits / Employee
-310.21K GBP
Market Cap
225.86M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Aclaris Therapeutics News
- 16 days ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 4 weeks ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 7 weeks ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
- 2 months ago - Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - PRNewsWire
- 2 months ago - Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - GlobeNewsWire